82 research outputs found
Two-dimensional Einstein manifolds in geometrothermodynamics
We present a class of thermodynamic systems with constant thermodynamic
curvature which, within the context of geometric approaches of thermodynamics,
can be interpreted as constant thermodynamic interaction among their
components. In particular, for systems constrained by the vanishing of the
Hessian curvature we write down the systems of partial differential equations.
In such a case it is possible to find a subset of solutions lying on a
circumference in an abstract space constructed from the first derivatives of
the isothermal coordinates. We conjecture that solutions on the characteristic
circumference are of physical relevance, separating them from those of pure
mathematical interest. We present the case of a one-parameter family of
fundamental relations that -- when lying in the circumference -- describe a
polytropic fluid
Comment on "Geometrothermodynamics of a Charged Black Hole of String Theory"
We comment on the conclusions found by Larra\~naga and Mojica regarding the
consistency of the Geoemtrothermodynamics programme to describe the critical
behaviour of a Gibbons-Maeda-Garfinkle-Horowitz-Strominger charged black hole.
We argue that making the appropriate choice of metric for the thermodynamic
phase space and, most importantly, considering the homogeneity of the
thermodynamic potential we obtain consistent results for such a black hole.Comment: Comment on arXiv:1012.207
Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO)
<p>Abstract</p> <p>Background</p> <p>Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory, non-infectious osteopathy that affects predominantly patients ≤ 18 years of age. There is no uniformly effective treatment. Our objective is to describe clinical, magnetic resonance imaging (MRI), and bone resorption response to intravenous pamidronate in pediatric CRMO.</p> <p>Methods</p> <p>We report our prospectively documented experience with all CRMO patients treated with pamidronate between 2003 and 2008 at a tertiary pediatric centre. Pamidronate was administered as intravenous cycles. The dose of pamidronate varied among subjects but was given as monthly to every 3 monthly cycles depending on the distance the patient lived from the infusion center. Maximum cumulative dose was ≤ 11.5 mg/kg/year. Pamidronate treatment was continued until resolution of MRI documented bone inflammation. Visual analog scale for pain (VAS) and bone resorption marker urine N-telopeptide/urine creatinine (uNTX/uCr) were measured at baseline, preceding each subsequent pamidronate treatment, at final follow-up, and/or at time of MRI confirmed CRMO flare. MRI of the affected site(s) was obtained at baseline, preceding every 2<sup>nd </sup>treatment, and with suspected CRMO recurrence.</p> <p>Results</p> <p>Nine patients (5 F: 4 M) were treated, with a median (range) age at treatment of 12.9 (4.5–16.3) years, and median (range) duration of symptoms of 18 (6–36) months. VAS decreased from 10/10 to 0–3/10 by the end of first 3–day treatment for all patients. The mean (range) time to complete MRI resolution of bone inflammation was 6.0 (2–12) months. The mean (confidence interval (CI)) baseline uNTX/uCr was 738.83 (CI 464.25, 1013.42)nmol/mmol/creatinine and the mean (CI) decrease from baseline to pamidronate discontinuation was 522.17 (CI 299.77, 744.56)nmol/mmol/creatinine. Median (range) of follow-up was 31.4 (24–54) months. Four patients had MRI confirmed CRMO recurrence, which responded to one pamidronate re-treatment. The mean (range) uNTX/uCr change as a monthly rate from the time of pamidronate discontinuation to flare was 9.41 (1.38–19.85)nmol/mmol/creatinine compared to -29.88 (-96.83–2.01)nmol/mmol/creatinine for patients who did not flare by the time of final follow-up.</p> <p>Conclusion</p> <p>Pamidronate resulted in resolution of pain and MRI documented inflammation in all patients. No patient flared while his/her uNTX/uCr remained suppressed. We propose that pamidronate is an effective second-line therapy in persistent CRMO.</p
- …